Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream could help kids with psoriasis

NCT ID NCT05172726

Disease control Sponsor: Organon and Co Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a cream called tapinarof for children aged 2 to 17 with plaque psoriasis, a skin condition causing red, scaly patches. The cream is applied once daily to see if it is safe and tolerable. About 58 children will take part in this open-label trial, meaning everyone knows they are getting the active cream.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tapinarof cream, 1%
What this could lead to
If successful, this could provide a new topical treatment option for children with plaque psoriasis, potentially improving symptom control.
What could go wrong
This is an early-phase, open-label study with only 58 participants, so results may not confirm effectiveness or safety for all children. Side effects like skin irritation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

58 people

The number who actually took part.

Started

Dec 2021

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female subjects ages 2 to 17 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months prior to the baseline visit * Subject with plaque psoriasis covering ≥ 3% of the BSA at screening and baseline * A PGA score of ≥ 2 at screening and baseline * Female subjects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use acceptable birth control methods * Must not be pregnant * Subject, subject's parent, or legal representative must be capable of giving written informed consent/assent Exclusion Criteria: * Psoriasis other than plaque variant * Any sign of infection of any of the psoriatic lesions * Immunocompromised at screening * Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upper limit of normal (ULN) * Screening total bilirubin \> 1.5x ULN * Current or chronic history of liver disease * Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix * Major surgery within 8 weeks prior to baseline or has a major surgery planned during the study * Known history of clinically significant drug or alcohol abuse in the last year prior to baseline * Use of any prohibited medication or procedure within the indicated period before the baseline visit until the completion of the study completion or study discontinuation * History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion may interfere with the subject's participation in the study, interpretation of results, safety of the subject or ability to understand and give informed consent * Pregnant or lactating females. * History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation * Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • Alliance Clinical Trials

    Waterloo, Ontario, N2J 1C4, Canada

  • Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana, 46250, United States

  • Dermatology Research Institute Inc.

    Calgary, Alberta, T2J7E1, Canada

  • Dermatology Specialists of Spokane

    Spokane, Washington, 99202, United States

  • First OC Dermatology

    Fountain Valley, California, 92708, United States

  • Innovaderm Research, Inc.

    Montreal, Quebec, H2X 2V1, Canada

  • Lynderm Research Inc.

    Markham, Ontario, L3P1X3, Canada

  • Mission Dermatology Center

    Rancho Santa Margarita, California, 92688, United States

  • Northwest Arkansas Clinical Trials Center, PLLC

    Rogers, Arkansas, 72758, United States

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611, United States

  • Olympian Clinical Research

    Tampa, Florida, 33615, United States

  • Options Research Group

    West Lafayette, Indiana, 47906, United States

  • Oregon Dermatology & Research Center

    Portland, Oregon, 97210, United States

  • RM Medical Research

    Miami Lakes, Florida, 33014, United States

  • Rejuvenation Laser Dermatology Clinics

    Edmonton, Alberta, T5J3S9, Canada

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida, 33014, United States

  • Skincare Studio INC

    St. John's, Newfoundland and Labrador, A1E1V4, Canada

  • Whitby Health Centre Dermatology Trials

    Whitby, Ontario, L1P0P9, Canada

  • Wright State Physicians Pharmacology Translational Unit

    Fairborn, Ohio, 45324, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.